Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmanex

This article was originally published in The Tan Sheet

Executive Summary

Supplement marketer drops appeal of Salt Lake City federal judge's March decision affirming FDA's determination company's Cholestin red yeast rice product is a drug. Firm originally appealed the ruling May 31, but filed a motion to dismiss the appeal Sept. 10, one day before its opening brief was due to be filed with the 10th Circuit U.S. Court of Appeals in Denver. Difficulties in prevailing on appeal, litigation costs contributed to company's decision. Firm introduced a reformulated version of Cholestin in July (1"The Tan Sheet" July 16, In Brief)

You may also be interested in...



Cholestin

New formulation contains Policor (policosanol), "beeswax-based" proprietary ingredient that inhibits cholesterol synthesis in liver, Pharmanex says July 9. NuSkin Enterprises division removed original red yeast rice-containing Cholestin from market following Utah federal court decision favoring FDA determination the product was a drug because it contained lovastatin, the active ingredient in Merck's Mevacor (1"The Tan Sheet" May 7, p. 15). Once-daily formula developed by Hauser replaces twice-daily red yeast rice dosage and is made with novel PoliSorb softgel delivery system. Thirty-count bottles marked "new and improved" are priced at $39.95

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS093044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel